⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
XNCR News
Xencor, Inc.
Xencor Presents Initial Data for XmAb819, a First-in-class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Clear Cell Renal Cell Carcinoma
businesswire.com
XNCR
Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation
prnewswire.com
GTBP
EVAX
RNXT
EDAP
XNCR
GTBP
EVAX
RNXT
EDAP
XNCR
Xencor Announces Presentation of Initial Phase 1 Dose-Escalation Results of XmAb819 in Clear Cell Renal Cell Carcinoma at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
businesswire.com
XNCR